Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Viatris Inc.NASDAQ: VTRS

Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026

Other non-cash items declines year over year

Q2 FY2026 other non-cash items of $261.4M fell 51.5% year over year, behind the -35.5% change in trailing-twelve-month other non-cash items. Sequentially, it rose 0.5% from the prior quarter.

Context

  • Other non-cash items amounted to 40.8% of revenue in FY2025, up 32.9 pp from a year earlier.
  • Other non-cash items increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -51.5% toward the trailing-twelve-month pace of -35.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$261.4M+0.5% QoQ
Last fiscal yearDec 2025
$5.84B+399.3% YoY
LTMJun 2026
$2.7B-35.5% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-51.5%——
1 year+399.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
5.84B USD
Year-over-year change
+399.3%
4-year CAGR
+64.5%

Other Non-Cash Items vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.5% is the 7th highest of 10, against a peer median of +128.9%.
  • Other non-cash items amounts to 18.3% of revenue for VTRS, versus a peer median of 5.3%.
VTRS Competitors
Other Non-Cash Items for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTRSViatris Inc.LTM Jun 2026$2.7B USD-35.5%—18.3%
BHCBausch Health Companies Inc.LTM Jun 2026$1.68B USD+2337.1%-90.7%15.5%
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹1.66B INR-90.3%—0.5%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$1.63B USD+4.4%-22.3%9.4%
OGNOrganon & Co.LTM Sep 2026$400.68M USD+489.2%+27.8%6.6%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$232.33M USD+128.9%+26.2%7.5%
ALKSAlkermes plcLTM Sep 2026$79.6M USD+1327.6%-42.0%4.5%
HLNHaleon plcFY2025£52.82M GBP-86.3%-46.0%0.5%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$37.96M USD+271.1%—5.3%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$12.05M USD-153.3%—1.3%
Peer median (excluding VTRS) —+128.9%-32.2%5.3%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
Deferred Income Tax675.7M(25.9M)(387.1M)(767.6M)(476.5M)
Stock-Based Compensation111.2M116.4M180.7M146.1M177.7M
Change in Working Capital(1.8B)(922.6M)(711.3M)(318.6M)(2.5B)
Accounts Receivables59.3M(240.3M)78.6M300.1M334.6M
Inventory(427.6M)(259.5M)(613.3M)(723.4M)(106.4M)
Accounts Payables(70.4M)170.2M314.7M36M(168M)
Other Working Capital(1.37B)(593M)(491.3M)68.7M(2.56B)
Other Non-Cash Items797.4M(1.28B)922.1M1.17B5.84B
Operating Cash Flow3.02B3B2.8B2.3B2.32B
Capital Expenditures(509.4M)(489.4M)(474.5M)(326M)(378.8M)
Acquisitions (Net)277M0(667.7M)(350M)0
Purchases of Investments(30.2M)(30.2M)(26.3M)(26M)(23.9M)
Sales of Investments29.8M29.9M26.3M26M23.9M
Other Investing Activities115M1.96B280.6M2.48B(48.9M)
Investing Cash Flow(117.8M)1.47B(764.1M)1.8B(427.7M)
Debt Repayment(2.1B)(3.28B)(1.25B)(3.71B)100K
Common Stock Issued03.3M3.1M2.5M2.6M
Common Stock Repurchased(17.4M)0(250M)(250M)(500.5M)
Dividends Paid(399M)(581.6M)(575.6M)(574.8M)(561.2M)
Other Financing Activities(496.5M)(19.5M)(229.8M)205.6M(234.9M)
Financing Cash Flow(3.01B)(3.88B)(2.3B)(4.33B)(1.29B)
Effect of Forex Changes(30.9M)(38.9M)(2.5M)(30.7M)17.6M
Net Change in Cash(143.8M)556.3M(268.9M)(257.5M)611.9M
Free Cash Flow2.51B2.51B2.33B1.98B1.94B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.